Previously, NIRF imaging using EpCAM antibodies have been demonstrated to detect orthotopic tumors in cell line-based xenograft models of head and neck, breast and colorectal cancer [24], as well as to visualize metastatic lymph nodes [34] and improve detection of tumor margins [35] in preclinical prostate cancer models. Here, EPCAM is linked to prostate carcinoma.